Starna Scientific?s Calibration and Reference Material manufacturing laboratory has extended the Starna range of Certified Reference Materials (CRMs), providing the most comprehensive range of UV/Visible/NIR materials currently available under the scope of ISO Guide 34 + ISO/IEC 17025 accreditation for Reference Material producers.
Starna Scientific’s Calibration and Reference Material manufacturing laboratory has extended the Starna range of Certified Reference Materials (CRMs), providing the most comprehensive range of UV/Visible/NIR materials currently available under the scope of ISO Guide 34 + ISO/IEC 17025 accreditation for Reference Material producers.
The CRMs are essential for ISO/IEC accredited laboratories, pharmaceutical QA/QC or metrology departments enabling the provision of Operational Qualification (OQ) and Performance Qualification (PQ) of UV/Visible/NIR instrumentation using ‘Industry Standard’ protocols.
Starna is the only Reference Material producer accredited to both ISO Guide 34 and ISO/IEC 17025 in the UV/Visible/NIR spectral range. The CRMs the company now provide extend the scope of available materials for spectral range, band width and photometric linearity.
“We now produce CRMs for wavelength and Transmittance scales, certified in accordance with ISO Guide 34 and ISO/IEC 17025, for the complete Far UV to NIR spectral region (190 – 2850 nm),” explained Keith Hulme, Starna’s Managing Director.
The Starna® Lifetime Guarantee is offered on all Starna® manufactured Certified Reference Materials (CRMs). The guarantee provides for a free of charge replacement should the assigned values move outside the expanded uncertainty budget within the recertification period of two years, subject to conditions of use/care and recertification by Starna at least every two years.
Contact details:
Starna Scientific
52-54 Fowler Road
Hainault
Essex
IG6 3UT
0208 5001264
sales@starna.co.ukwww.starna.co.uk
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.